Literature DB >> 18838168

Disruption of T cell suppression in chronic lymphocytic leukemia by CD200 blockade.

Christian P Pallasch1, Sabine Ulbrich, Reinhild Brinker, Michael Hallek, Robert A Uger, Clemens-Martin Wendtner.   

Abstract

CD200 plays a key role in regulating the immune system and has been shown to be upregulated on the surface of different tumors including chronic lymphocytic leukemia. In this study we addressed the effects of CD200 over-expression in CLL cells on autologous T cells in a mixed lymphocyte reaction system. We used native and CD40 ligand (CD40L)-stimulated CLL cells as antigen-presenting cells (APCs) to expand autologous T cells of 14 patients. T cell proliferation over 3 weeks of in vitro culture was significantly enhanced compared to control cells when using CD40L-stimulated APCs and the anti-CD200 antibody 1B9 (p=0.0004). CD200 blockade was further shown to stimulate antigen-specific T cell responses towards the CLL-associated antigen fibromodulin (p=0.04). Finally, the number of CD4+/CD25high/FOXP3+ T cells (T(reg)) was significantly decreased adding anti-CD200 antibody (p=0.04). In summary, CD200 blockade may provide therapeutic benefits in CLL by augmenting an antigen-specific T cell response with suppression of regulatory T cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18838168     DOI: 10.1016/j.leukres.2008.08.021

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  22 in total

1.  Long term potentiation is impaired in membrane glycoprotein CD200-deficient mice: a role for Toll-like receptor activation.

Authors:  Derek A Costello; Anthony Lyons; Stephanie Denieffe; Tara C Browne; F Fionnuala Cox; Marina A Lynch
Journal:  J Biol Chem       Date:  2011-08-11       Impact factor: 5.157

2.  Ibrutinib treatment improves T cell number and function in CLL patients.

Authors:  Meixiao Long; Kyle Beckwith; Priscilla Do; Bethany L Mundy; Amber Gordon; Amy M Lehman; Kami J Maddocks; Carolyn Cheney; Jeffrey A Jones; Joseph M Flynn; Leslie A Andritsos; Farrukh Awan; Joseph A Fraietta; Carl H June; Marcela V Maus; Jennifer A Woyach; Michael A Caligiuri; Amy J Johnson; Natarajan Muthusamy; John C Byrd
Journal:  J Clin Invest       Date:  2017-07-17       Impact factor: 14.808

Review 3.  Immune reconstitution in chronic lymphocytic leukemia.

Authors:  John C Riches; Alan G Ramsay; John G Gribben
Journal:  Curr Hematol Malig Rep       Date:  2012-03       Impact factor: 3.952

Review 4.  Challenges and future perspectives of T cell immunotherapy in cancer.

Authors:  Maria Teresa P de Aquino; Anshu Malhotra; Manoj K Mishra; Anil Shanker
Journal:  Immunol Lett       Date:  2015-06-19       Impact factor: 3.685

Review 5.  Regulatory B lymphocyte functions should be considered in chronic lymphocytic leukemia.

Authors:  Audrey Mohr; Yves Renaudineau; Cristina Bagacean; Jacques-Olivier Pers; Christophe Jamin; Anne Bordron
Journal:  Oncoimmunology       Date:  2016-03-16       Impact factor: 8.110

6.  Decreased CD200R expression on monocyte-derived macrophages correlates with Th17/Treg imbalance and disease activity in rheumatoid arthritis patients.

Authors:  Song Gao; Bing Hao; Xu Feng Yang; Wei Qian Chen
Journal:  Inflamm Res       Date:  2014-02-05       Impact factor: 4.575

7.  Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.

Authors:  Joseph A Fraietta; Kyle A Beckwith; Prachi R Patel; Marco Ruella; Zhaohui Zheng; David M Barrett; Simon F Lacey; Jan Joseph Melenhorst; Shannon E McGettigan; Danielle R Cook; Changfeng Zhang; Jun Xu; Priscilla Do; Jessica Hulitt; Sagar B Kudchodkar; Alexandria P Cogdill; Saar Gill; David L Porter; Jennifer A Woyach; Meixiao Long; Amy J Johnson; Kami Maddocks; Natarajan Muthusamy; Bruce L Levine; Carl H June; John C Byrd; Marcela V Maus
Journal:  Blood       Date:  2016-01-26       Impact factor: 22.113

8.  Upregulation of CD200 is associated with Foxp3+ regulatory T cell expansion and disease progression in acute myeloid leukemia.

Authors:  Ali Memarian; Maryam Nourizadeh; Farimah Masoumi; Mina Tabrizi; Amir Hossein Emami; Kamran Alimoghaddam; Jamshid Hadjati; Mahroo Mirahmadian; Mahmood Jeddi-Tehrani
Journal:  Tumour Biol       Date:  2012-11-18

9.  Suppression of Glut1 and Glucose Metabolism by Decreased Akt/mTORC1 Signaling Drives T Cell Impairment in B Cell Leukemia.

Authors:  Peter J Siska; Gerritje J W van der Windt; Rigel J Kishton; Sivan Cohen; William Eisner; Nancie J MacIver; Arnon P Kater; J Brice Weinberg; Jeffrey C Rathmell
Journal:  J Immunol       Date:  2016-08-10       Impact factor: 5.422

10.  Selective elimination of a chemoresistant side population of B-CLL cells by cytotoxic T lymphocytes in subjects receiving an autologous hCD40L/IL-2 tumor vaccine.

Authors:  A E Foster; F V Okur; E Biagi; A Lu; G Dotti; E Yvon; B Savoldo; G Carrum; M A Goodell; H E Heslop; M K Brenner
Journal:  Leukemia       Date:  2010-01-14       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.